Spots Global Cancer Trial Database for Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

Official Title: Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

Study ID: NCT02654041

Conditions

Glioblastoma Multiforme (GBM)

Interventions

Combined T3 and Methimazole treatment

Study Description

Brief Summary: The objective of the study is to assess the safety and efficacy of treatment with hypothyroxinemia adjunct to conventional therapies in GBM patients.

Detailed Description: Since T4 (thyroxine) is a potent growth factor in numerous cancer types, the interventional approach will be to achieve thyroxine deprivation (hypothyroxinemia).This can be achieved by using a dual approach: T3 and methimazole to provide longer term inhibition of thyroid hormone synthesis.